|
Genelabs Technologies, Inc. |
|
|
505 Penobscot Drive
Redwood City, CA 94063 USA
phone:(650) 369-9500
fax:(650) 368-0709
|
|
| Symbol |
GNLB |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
94 |
|
|
| www.genelabs.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| A variety of drug candidates include treatments for lupus and hepatitis C. |
|
| Management |
| James A. D. Smith, President and Chief Executive Officer; Ronald C. Griffith, Ph.D., Chief Scientific Officer; Heather C. Keller, Vice President, Business Strategy and Secretary; Kenneth E. Schwartz, M.D., Vice President, Medical Affairs; Roy J. Wu, Vice President, Business Development; Peter R. Young, Ph.D., Vice President, Biology |
| |
|
|
|
|
|
|
|
| Keywords |
| lupus, antifungal, hepatitis C, HCV |
|
|
|
| Description |
|
Genelabs Technologies, Inc. is a biopharmaceutical company engaged in the discovery and development of pharmaceutical products. Genelabs has built drug discovery and clinical development capabilities that can support various research and development projects. |
|
| Products / Services |
Genelabs is pursuing regulatory approval of Prestara, its investigational drug for women with systemic lupus erythematosus. The company is also pursuing the discovery of novel antimicrobial and antiviral compounds for treatment of infections that are not well treated with currently available drugs.
|
|
| Technology / Differentiation |
| Prestara (known in development as GL701) is being developed by Genelabs as an investigational new drug for women with systemic lupus erythematosus (SLE or lupus), a chronic autoimmune disease for which no new drug has been approved in the U.S. in more than 40 years. Prior to Genelabs' work in this area, there had been no large, well-controlled clinical trials for assessing the safety and efficacy of new drugs for this disease. Working together with internationally recognized lupus experts, Genelabs designed and conducted pioneering clinical trials using Prestara as an investigational drug for women with SLE. These efforts resulted in the submission of a new drug application (NDA) to the Food and Drug Administration (FDA). |
|
| Market / Customers |
Lupus affects primarily women-generally diagnosed while of childbearing age-and can cause significant morbidity and disruption of daily activities. Lupus is characterized by alternating periods of active disease symptoms (flares) and periods of quiescence. Inflammation occurs in all patients, and symptoms can include irreversible damage to almost every organ and organ system, including the musculoskeletal, renal, pulmonary, neurological, cardiovascular, and cutaneous systems, as well as depression and severe fatigue, all of which can reduce their health-related quality of life. Glucocorticoids are often used to treat lupus, yet are associated with significant side effects such as bone loss and accelerated atherosclerosis.
|
|
| Strategy |
The company is concentrating its capabilities on three core programs: the development of its late-stage product for lupus, Prestara; the discovery of follow-on compounds to its preclinical antifungal drug candidate, and the discovery of novel lead compounds that selectively inhibit replication of the hepatitis C virus (HCV).
|
|
| Status |
| Genelabs has completed three Phase III double-blind, randomized, placebo controlled clinical trials of Prestara for women with systemic lupus erythematosus. On January 7th, 2009, Genelabs merged with GlaxoSmithKline. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
